In vitro antibacterial acitivity of Naproxen and its combination with ciprofloxacin

Sultan Öğmen Seven, Ertuğrul Özbil, Açelya Mavideniz, Mehmet İlktaç
{"title":"In vitro antibacterial acitivity of Naproxen and its combination with ciprofloxacin","authors":"Sultan Öğmen Seven, Ertuğrul Özbil, Açelya Mavideniz, Mehmet İlktaç","doi":"10.54994/emujpharmsci.1506693","DOIUrl":null,"url":null,"abstract":"Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), is commonly used to reduce fever, and to treat pain and inflammation caused by several conditions. Previously, naproxen was evaluated for its antimicrobial potency in various studies. In our study, we aimed to demonstrate the antibacterial and synergistic activities of naproxen and ciprofloxacin against various Gram-positive and Gram-negative bacteria including, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603. The results showed promising antibacterial activity against tested Gram-positive bacteria. However, there was no effect on Gram-negative bacteria. Additionally, checkerboard assays did not reveal any additive or synergistic activity when combined with Ciprofloxacin. Collectively, our study's data show naproxen's selectivity against Gram-positive bacteria. This result suggests that naproxen can be further used as a potential source of antibiotics against Gram-positive bacteria.","PeriodicalId":351131,"journal":{"name":"EMU Journal of Pharmaceutical Sciences","volume":"30 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMU Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54994/emujpharmsci.1506693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), is commonly used to reduce fever, and to treat pain and inflammation caused by several conditions. Previously, naproxen was evaluated for its antimicrobial potency in various studies. In our study, we aimed to demonstrate the antibacterial and synergistic activities of naproxen and ciprofloxacin against various Gram-positive and Gram-negative bacteria including, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603. The results showed promising antibacterial activity against tested Gram-positive bacteria. However, there was no effect on Gram-negative bacteria. Additionally, checkerboard assays did not reveal any additive or synergistic activity when combined with Ciprofloxacin. Collectively, our study's data show naproxen's selectivity against Gram-positive bacteria. This result suggests that naproxen can be further used as a potential source of antibiotics against Gram-positive bacteria.
萘普生及其与环丙沙星复方制剂的体外抗菌活性
萘普生是一种非甾体抗炎药(NSAID),常用于退烧、治疗多种疾病引起的疼痛和炎症。此前,已有多项研究对萘普生的抗菌效力进行了评估。在我们的研究中,我们旨在证明萘普生和环丙沙星对各种革兰氏阳性和革兰氏阴性细菌的抗菌和协同活性,包括粪肠球菌 ATCC 29212、金黄色葡萄球菌 ATCC 25923、大肠埃希菌 ATCC 25922 和肺炎克雷伯菌 ATCC 700603。结果表明,它对测试的革兰氏阳性菌具有良好的抗菌活性。但是,对革兰氏阴性菌没有效果。此外,在与环丙沙星联用时,棋盘格试验并未显示出任何相加或协同活性。总之,我们的研究数据显示了萘普生对革兰氏阳性菌的选择性。这一结果表明,萘普生可进一步用作抗革兰氏阳性菌的潜在抗生素来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信